🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Refractory Diffuse Large B Cell Lymphoma (DLBCL)

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site📍 Milan Incyte Biosciences Italy S.r.l Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites📍 Anchorage📍 Clovis📍 Fullerton Hoffmann-La Roche · Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma NCT07126236Phase 219 sites📍 Seville📍 Zaragoza📍 Palma de Mallorca Grupo Español de Linfomas y Transplante Autólogo de Médula … · Tests: Epcoritamab, Epcoritamab, tafasitamab and lenalidomide Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866Phase 251 sites📍 Graz📍 Innsbruck📍 Linz Miltenyi Biomedicine GmbH · Tests: MB-CART2019.1, Standard of Care Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848Phase 11 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Vancomycin 125mg, Radiation Therapy, CAR-T Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652Phase 21 site📍 Monterrey Hospital Universitario Dr. Jose E. Gonzalez · Tests: Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies NCT05836896Phase 11 site📍 Dresden Technische Universität Dresden · Tests: MDC-CAR-BCMA001 (BCMA directed CAR T-cells) A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07570017Phase 12 sites📍 Guangzhou📍 Shanghai Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, R-GemOx A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region NCT07065344n/a21 sites📍 Al Mansurah📍 Alexandria📍 Cairo AstraZeneca A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL NCT07409428Phase 350 sites📍 Shanghai📍 Baoding📍 Beijing Hutchmed · Tests: HMPL-760, HMPL-760 Placebo, R-GemOx A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL NCT07255963Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Pirtobrutinib, Lisaftoclax, Rituximab Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites📍 Richmond📍 Nedlands📍 Haifa ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy NCT06854159Phase 21 site📍 Sacramento University of California, Davis · Tests: Chimeric Antigen Receptor T-Cell Therapy, Odronextamab Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031Phase 11 site📍 Tianjin Shanghai Exuma Biotechnology Ltd. · Tests: C402-CD19-CAR Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. NCT07489989Phase 21 site📍 Beijing Daihong Liu · Tests: CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma NCT07788118Phase 1, Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: 7×19-THEMIS CAR-T cells Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site📍 Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. · Tests: Tafasitamab and Lenalidomide Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma NCT06919939Phase 21 site📍 Miami University of Miami · Tests: Epcoritamab, Loncastuximab Tesirine A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017Phase 2, Phase 3135 sites📍 Glendale📍 Beverly Hills📍 Walnut Creek Merck Sharp & Dohme LLC · Tests: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: ultra-fraction radiotherapy Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse NCT03356054Phase 1, Phase 21 site📍 Rotterdam Stichting Hemato-Oncologie voor Volwassenen Nederland · Tests: R-DHAP, Brentuximab Vedotin Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL NCT06570447Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Glofitamab, Chidamide Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384Phase 19 sites📍 Birmingham📍 Duarte📍 Sacramento National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL NCT04502394Phase 1, Phase 245 sites📍 Goshen📍 Cincinnati📍 Columbus Kartos Therapeutics, Inc. · Tests: KRT-232, acalabrutinib Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07523737Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy